To date, the coronavirus disease 2019 (COVID-19) caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) has determined 399,600,607 cases and 5,757,562 …

Immune checkpoint blockade (ICB) therapies have achieved remarkable clinical responses
in patients with many different types of cancer; however, most patients who receive ICB …

Tumor-infiltrating dendritic cells (DCs) assume varied functional states that impact anti-tumor
immunity. To delineate the DC states associated with productive anti-tumor T cell immunity …

Simple Summary Immunotherapies have revolutionized the field of cancer therapeutics, yet
a substantial subset of patients fail to respond. Recent efforts have focused on identifying …

Cytokines are soluble proteins that mediate cell-to-cell communication. Based on the
discovery of the potent anti-tumour activities of several pro-inflammatory cytokines in animal …

Janus kinase-signal transducer and activator of transcription (JAK-STAT) signaling mediates
almost all immune regulatory processes, including those that are involved in tumor cell …

Combinatorial clinical trials of PARP inhibitors with immunotherapies are ongoing, yet the
immunomodulatory effects of PARP inhibition have been incompletely studied. Here, we …

Local immunotherapy ideally stimulates immune responses against tumors while avoiding
toxicities associated with systemic administration. Current strategies for tumor-targeted …

The role of B cells in anti-tumour immunity is still debated and, accordingly,
immunotherapies have focused on targeting T and natural killer cells to inhibit tumour …

Clearance of apoptotic cells by macrophages prevents excessive inflammation and supports
immune tolerance. Here, we examined the effect of blocking apoptotic cell clearance on anti …